NEKTAR THERAPEUTICS

For the period ended Dec 31, 2023. Filed Mar 5, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 5, 2024

NKTR$37.78-0.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets at December 31, 2023 and 2022

(In thousands, except par value information)

	December 31,
	2023	2022
ASSETS
Current assets:
Cash and cash equivalents	$35,277	$88,227
Short-term investments	268,339	416,750
Accounts receivable	1,205	5,981
Inventory	16,101	19,202
Other current assets	9,779	15,808
Total current assets	330,701	545,968
Long-term investments	25,825	—
Property, plant and equipment, net	18,856	32,451
Operating lease right-of-use assets	18,007	53,435
Goodwill	—	76,501
Other assets	4,644	2,245
Total assets	$398,033	$710,600
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$9,848	$12,980
Accrued expenses	22,162	36,557
Operating lease liabilities, current portion	19,259	18,667
Total current liabilities	51,269	68,204
Operating lease liabilities, less current portion	98,517	112,829
Liabilities related to the sales of future royalties, net	112,625	155,378
Other long-term liabilities	4,635	7,551
Total liabilities	267,046	343,962
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000 shares authorized; no shares designated, issued or outstanding at December 31, 2023 or 2022	—	—
Common stock, $0.0001 par value; 300,000 shares authorized; 191,384 shares and 188,560 shares issued and outstanding at December 31, 2023 and 2022, respectively	19	19
Capital in excess of par value	3,608,137	3,574,719
Accumulated other comprehensive income (loss)	80	(6,907)
Accumulated deficit	(3,477,249)	(3,201,193)
Total stockholders’ equity	130,987	366,638
Total liabilities and stockholders’ equity	$398,033	$710,600

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.